Tom Lemberg, Curebase CEO

DCT start­up look­ing to forge bet­ter com­mu­ni­ty re­la­tion­ships nets a mod­est Se­ries B

The de­cen­tral­ized clin­i­cal tri­al in­dus­try went through a huge boom dur­ing the Covid-19 pan­dem­ic as biotechs and Big Phar­ma com­pa­nies alike were forced to shift gears. Look­ing to cap­i­tal­ize on that mo­men­tum, a San Fran­cis­co start­up is rais­ing funds to en­sure clos­er part­ner­ships with the com­mu­ni­ties DCTs serve.

Cure­base pulled to­geth­er a $40 mil­lion Se­ries B on Thurs­day, rough­ly 13 months af­ter clos­ing its Se­ries A. While on the sur­face this may seem like an­oth­er DTC com­pa­ny, CEO Tom Lem­berg tells End­points News the com­pa­ny is look­ing to sep­a­rate it­self from the pack by go­ing straight to the com­mu­ni­ty to bring greater di­ver­si­ty to clin­i­cal tri­als.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.